Afrezza Product and Company Overview
Afrezza is an ultra-rapid-acting form of inhalable or mealtime insulin that is currently in its late stages of clinical investigation. Afrezza is purposely developed to provide treatment to adults suffering from type one or type two diabetes mellitus and Afrezza will be suited for the control of hyperglycemia. Afrezza is a drug-device that is combined with Afrezza inhalation powder that has been measured into meter level representing single dose cartridges and the Afrezza inhaler (Datamonitor Report 4). Afrezza is a proprietary product being developed by MannKind Corporation.
MannKind Corporation is a US based biopharmaceutical company involved in the discovery, development, and commercialization ...
